RenaissanceRe Holdings Ltd. Announces Quarterly Dividend

Board of Directors Approves Share Repurchase Program up to an Aggregate of $500 million

PEMBROKE, Bermuda--(BUSINESS WIRE)-- The Board of Directors of RenaissanceRe Holdings Ltd. (NYSE: RNR) announced today a quarterly dividend of $0.30 per common share on its common stock.

The dividend is payable on June 30, 2015 to shareholders of record on June 15, 2015.

In addition, the Board of Directors approved an increase in RenaissanceRe's share repurchase program, bringing the total current authorization to $500 million. This authorization includes the remaining amounts available under prior authorizations. Under this program, RenaissanceRe may repurchase shares of its common stock in the open market based on, among other things, its ongoing capital requirements and expected cash flows, and the market price of its common shares. The repurchase program does not have an established expiration date.

RenaissanceRe Holdings Ltd. is a global provider of reinsurance and insurance. The Company’s business consists of three reportable segments: (1) Catastrophe Reinsurance, which includes catastrophe reinsurance and certain property catastrophe joint ventures managed by the Company’s ventures unit; (2) Specialty Reinsurance, which includes specialty reinsurance and certain specialty joint ventures managed by the Company’s ventures unit; and (3) Lloyd’s, which includes reinsurance and insurance business written through RenaissanceRe Syndicate 1458.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150520006543/en/

Investor:
RenaissanceRe Holdings Ltd.
Rohan Pai, 441-295-4513
Director – Corporate Finance
or
Media:
Kekst and Company
Peter Hill or Dawn Dover, 212-521-4800

Source: RenaissanceRe Holdings Ltd.

You May Also Be Interested In

• The Baja Is Back: A Race Against Blindness Offers One Final Chance to Win $350,000 Adventure Truck Prize
• CoreAgeRx Launches Advanced Preventive Longevity Protocols Featuring Microdosing Semaglutide, Microdosing Tirzepatide, and Sermorelin Therapies
• NIZARLINE Marks Global Expansion and Strategic Evolution Under Founder and CEO Kudra Mohammed